Compare SB & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SB | ARDX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.9M | 862.3M |
| IPO Year | 2008 | 2014 |
| Metric | SB | ARDX |
|---|---|---|
| Price | $8.64 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $9.50 | ★ $12.90 |
| AVG Volume (30 Days) | 1.4M | ★ 4.1M |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $16.80 | $19.98 |
| Revenue Next Year | N/A | $27.70 |
| P/E Ratio | $16.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.15 | $3.18 |
| 52 Week High | $9.31 | $8.40 |
| Indicator | SB | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 29.24 |
| Support Level | $8.02 | N/A |
| Resistance Level | $9.19 | $3.63 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 64.97 | 12.50 |
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain, and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services. The company generates almost all of its revenue from Time Charters.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.